Do you want to read an article? Please log in or register.
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study
Related content
RECOMMENDED
Parkinson’s Disease
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
Lancet Neurol.
Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D, CTH-300 Study investigators.
doi: 10.1016/S1474-4422(19)30396-5.
RECOMMENDED
Parkinson’s Disease
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Neurol.
LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C, SPAN-PD Study Investigators
doi: 10.1016/S1474-4422(18)30405-8.
Progression marker of Parkinson’s disease: a 4-year multi-site imaging study
Brain Neurology Journ.
Burciu RG, Ofori E, Archer DB, Wu SS, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE
doi: 10.1093/brain/awx146.
Aging and Cognitive Functions
Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study
J Neurol.
Amboni M, Iuppariello L, Iavarone A, Fasano A, Palladino R, Rucco R, Picillo M, Lista I, Varriale P, Vitale C, Cesarelli M, Sorrentino G, Barone P
doi: 10.1007/s00415-018-8973-x.
Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study
Neurology.
Cilia R, Laguna J, Cassani E, Cereda E, Pozzi NG, Isaias IU, Contin M, Barichella M, Pezzoli G
doi: 10.1212/
Alzheimer’s Disease
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
Lancet Neurol
Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E, TOMMORROW study investigators.
doi: 10.1016/S1474-4422(21)00043-0
RECOMMENDED
Parkinson’s Disease
Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)
Mov Disord.
Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T, Trenkwalder C; DeNoPa Study Group
doi: 10.1002/mds.27492.
Parkinson’s Disease
Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study
Lancet Neurol.
Vitek JL, Jain R, Chen L, Tröster AI, Schrock LE, House PA, Giroux ML, Hebb AO, Farris SM, Whiting DM, Leichliter TA, Ostrem JL, San Luciano M, Galifianakis N, Verhagen Metman L, Sani S, Karl JA, Siddiqui MS, Tatter SB, Ul Haq I, Machado AG, Gostkowski M, Tagliati M, Mamelak AN, Okun MS, Foote KD, Moguel-Cobos G, Ponce FA, Pahwa R, Nazzaro JM, Buetefisch CM, Gross RE, Luca CC, Jagid JR, Revuelta GJ, Takacs I, Pourfar MH, Mogilner AY, Duker AP, Mandybur GT, Rosenow JM, Cooper SE, Park MC, Khandhar SM, Sedrak M, Phibbs FT, Pilitsis JG, Uitti RJ, Starr PA
doi: 10.1016/S1474-4422(20)30108-3.
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
Lancet Neurol.
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A
doi: 10.1016/S1474-